IL218935A0 - Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors - Google Patents

Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors

Info

Publication number
IL218935A0
IL218935A0 IL218935A IL21893512A IL218935A0 IL 218935 A0 IL218935 A0 IL 218935A0 IL 218935 A IL218935 A IL 218935A IL 21893512 A IL21893512 A IL 21893512A IL 218935 A0 IL218935 A0 IL 218935A0
Authority
IL
Israel
Prior art keywords
biomarkers
predicting
inhibitors
sensitivity
response
Prior art date
Application number
IL218935A
Other languages
English (en)
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of IL218935A0 publication Critical patent/IL218935A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL218935A 2009-10-02 2012-03-29 Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors IL218935A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24827009P 2009-10-02 2009-10-02
US25580509P 2009-10-28 2009-10-28
US32377110P 2010-04-13 2010-04-13
US38068510P 2010-09-07 2010-09-07
PCT/US2010/051341 WO2011041785A1 (en) 2009-10-02 2010-10-04 Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors

Publications (1)

Publication Number Publication Date
IL218935A0 true IL218935A0 (en) 2012-07-31

Family

ID=43128291

Family Applications (1)

Application Number Title Priority Date Filing Date
IL218935A IL218935A0 (en) 2009-10-02 2012-03-29 Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors

Country Status (11)

Country Link
US (1) US20110212845A1 (enExample)
EP (1) EP2483686A1 (enExample)
JP (1) JP2013506836A (enExample)
KR (1) KR20120104196A (enExample)
AU (1) AU2010300307A1 (enExample)
BR (1) BR112012007555B1 (enExample)
CA (1) CA2776278A1 (enExample)
IL (1) IL218935A0 (enExample)
IN (1) IN2012DN03817A (enExample)
MX (1) MX2012003997A (enExample)
WO (1) WO2011041785A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212773D0 (en) * 2012-07-18 2012-08-29 Ucl Business Plc Vascular remodelling
US9146545B2 (en) 2012-11-27 2015-09-29 Honeywell International Inc. Multivariable control system for setpoint design
TWI582239B (zh) * 2013-03-11 2017-05-11 諾華公司 與ｗｎｔ抑制劑相關之標記
KR101593595B1 (ko) * 2013-10-08 2016-02-12 한국생명공학연구원 Ｃｘ－４９４５를 유효성분으로 함유하는 스플라이싱 조절제
WO2015053452A1 (ko) * 2013-10-08 2015-04-16 한국생명공학연구원 Ｃｘ－４９４５를 유효성분으로 함유하는 스플라이싱 조절제
DK3108255T3 (da) * 2014-02-18 2020-11-09 Inst Nat Sante Rech Med Fremgangsmåder og farmaceutiske sammensætninger til behandling af sygdomme medieret af nrp-1/obr-komplekssignalvejen
WO2016008975A1 (en) * 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
WO2016133860A1 (en) * 2015-02-16 2016-08-25 Board Of Regents Of The University Of Nebraska Cancer biomarkers and methods of use thereof
GB202102895D0 (en) * 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2023190820A1 (ja) * 2022-03-30 2023-10-05 公立大学法人福島県立医科大学 抗ＣＫ２α抗体又はその断片
CN115160341B (zh) * 2022-07-18 2023-07-18 中国医学科学院医学实验动物研究所 苯并噁嗪类化合物及其药物用途
KR102641010B1 (ko) * 2023-12-04 2024-02-28 대한민국 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200715636A (en) 2005-10-04 2007-04-16 Antig Tech Co Ltd Method of controlling fuel concentration used in direct liquid fuel cell
US7956064B2 (en) 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
US8488289B2 (en) 2006-09-27 2013-07-16 International Rectifier Corporation Current protection circuit for intelligent power switch
US20090035609A1 (en) 2007-07-31 2009-02-05 Apple Inc. Intelligent universal rechargeable batteries for battery charging system for mobile and accessory devices

Also Published As

Publication number Publication date
US20110212845A1 (en) 2011-09-01
EP2483686A1 (en) 2012-08-08
BR112012007555A2 (pt) 2016-10-25
AU2010300307A1 (en) 2012-05-24
JP2013506836A (ja) 2013-02-28
MX2012003997A (es) 2012-07-25
IN2012DN03817A (enExample) 2015-08-28
BR112012007555B1 (pt) 2020-09-29
KR20120104196A (ko) 2012-09-20
WO2011041785A1 (en) 2011-04-07
CA2776278A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
HUS1900012I1 (hu) Vegyületek és készítmények protein-kináz inhibitorokként
CY2019009I2 (el) Αναστολεις πρωτεϊνικων κινασων
IL256728A (en) Systems for detecting drugs and autoantibodies against TNF
EP2387572A4 (en) PROTEIN KINASE C HEMMER AND ITS USE
PL2990421T3 (pl) Przeciwciała anty-ceacam1 oraz sposoby ich stosowania
ZA201300921B (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity
EP2694517A4 (en) PROTEIN KINASE INHIBITORS
EP2734205A4 (en) HETEROCYCLIC PROTEIN KINASE HEMMER
PL3085773T3 (pl) Zastosowanie przeciwciał il-1 alfa
IL208719A0 (en) Inhibitors of protein kinases
EP2632898A4 (en) HETEROCYCLIC TYROSINE KINASE HEMMER
BRPI1013623A2 (pt) inibidores de ligação de proteína cinase
ZA201005868B (en) Inhibitors of protein tyrosine kinase activity
IL232559B (en) Thianopyrimidines as atypical protein c kinase inhibitors
DK2368118T3 (da) Biomarkører til inhibitorer med anti-angiogen aktivitet
PL2627669T3 (pl) Biomarkery cytokinowe jako biomarkery prognostyczne odpowiedzi klinicznej na octan glatirameru
EP3190416A4 (en) Biomarker for predicting sensitivity to protein kinase inhibitor and use thereof
EP2426149A4 (en) ANTI-CADHERIN ANTIBODY
IL208702A0 (en) Inhibitors of ikk-b serine-threonine protein kinase
IL216580A0 (en) Use of anti-sparc antibodies to predict response to chemothrapy
EP2478364A4 (en) ANTIBODY DETECTION
EP2462515A4 (en) METHODS OF ANALYZING FIXING TEST DATA NEARBY
EP2397481A4 (en) INHIBITOR OF CASEINKINASE 1DELTA AND CASEIN KINASE 1EPSILONE
SG10201406505WA (en) Methods for the detection of fatty-acylated proteins
EP2591368A4 (en) METHOD FOR DETERMINING ETHANOL CONSUMPTION